• Strategic Disruption of Cancer Metabolism: 7ACC2’s Dual Mech

  2026-04-30

  This thought-leadership article guides translational researchers through the evolving landscape of cancer metabolism, focusing on the strategic deployment of 7ACC2—a potent monocarboxylate transporter 1 inhibitor. Integrating mechanistic insights, including the interplay between lactate flux and immunometabolic checkpoints such as the 25-hydroxycholesterol–AMPK–STAT6 axis, the piece offers actionable protocols and visionary guidance for advancing next-generation oncology interventions.

• VX-745: Structural Mechanisms and Assay Optimization for p38

  2026-04-29

  Explore how VX-745, a potent p38α MAPK inhibitor, advances research through structural insights and practical assay optimization. This article uniquely bridges conformational biology with actionable protocols for inflammation and cancer research.

• L1023 Anti-Cancer Compound Library: High-Impact Workflows &

  2026-04-29

  The L1023 Anti-Cancer Compound Library empowers researchers to rapidly screen 1,164 validated compounds, targeting critical cancer pathways from BRAF kinase to mTOR. This guide delivers actionable workflows, expert troubleshooting advice, and data-driven insights—ensuring robust, reproducible results in cancer research and drug discovery.

• NAD+/NADH Homeostasis in Fungal Hypoxia: Metabolic Adaptatio

  2026-04-28

  This review dissects how NAD+/NADH homeostasis enables filamentous fungi to adapt metabolically to hypoxic environments, directly influencing the biosynthesis of organic acids and secondary metabolites. The findings reveal mechanistic links between redox regulation, energy conservation, and metabolite production, offering practical insights for optimizing fungal biotechnology applications.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody: Technical Workflow

  2026-04-28

  The HRP Goat Anti-Rabbit IgG (H+L) Antibody provides sensitive, specific detection of rabbit primary antibodies in common immunoassays such as Western blot, ELISA, and IHC. It is not suitable for diagnostic or medical applications and should be used strictly according to recommended protocols to maintain signal fidelity and reduce background.

• BML-277: Precision Tool for Dissecting Chk2–cGAS Axis in DNA

  2026-04-27

  Discover how BML-277, a potent Chk2 inhibitor, enables advanced investigation of the Chk2–cGAS signaling axis in DNA damage response research. This article delivers unique insights into practical assay design and mechanistic implications for genome stability and radioprotection.

• CD163+ Macrophages Drive Granulosa Cell Apoptosis in PCOS

  2026-04-27

  This study uncovers how increased activation of CD163+ macrophages in the ovary elevates granulosa cell apoptosis and inflammatory signaling in polycystic ovary syndrome (PCOS). The findings advance understanding of inflammatory microenvironmental mechanisms underlying PCOS pathogenesis and offer new entry points for targeted research on ovarian dysfunction.

• Acridine Orange hydrochloride: Technical Use and QC Guidance

  2026-04-26

  Acridine Orange hydrochloride enables differential staining of DNA and RNA for applications such as cell cycle analysis, apoptosis detection, and flow cytofluorometric nucleic acid staining. This guide details best-practice handling and workflow integration. The product is not recommended for protocols requiring long-term storage of dye solutions or applications outside nucleic acid staining.

• Cy5 NHS ester(Et): Technical Guidance for Protein Labeling

  2026-04-25

  Cy5 NHS ester(Et) enables direct, water-soluble fluorescent labeling of primary amines in proteins and biomolecules, supporting immunofluorescence, flow cytometry, and fluorescence microscopy. It is not suitable for workflows requiring ethanol solubility or long-term storage of dye solutions. Proper solubilization, prompt use, and adherence to storage guidelines are essential for reliable results.

• FITC Goat Anti-Mouse IgG (H+L) Antibody: Protocol & Workflow

  2026-04-24

  The FITC Goat Anti-Mouse IgG (H+L) Antibody addresses the need for sensitive, specific detection of mouse IgG in immunofluorescence and flow cytometry workflows. It is suitable for applications requiring reliable signal amplification but should not be used outside the scope of mouse IgG detection or in protocols incompatible with FITC-conjugated reagents.

• Rapamycin (Sirolimus): Advanced mTOR Inhibition Workflows

  2026-04-24

  Rapamycin (Sirolimus) is the benchmark mTOR inhibitor for dissecting cell proliferation, apoptosis, and metabolic signaling in cancer and neurobiology research. This guide details stepwise protocols, troubleshooting strategies, and the latest comparative insights to maximize reproducibility and innovation with APExBIO’s Rapamycin.

• Neuroinflammatory Pathways in Trigeminal Neuralgia: Piezo2 A

  2026-04-23

  Liao et al. elucidate how chronic trigeminal nerve root compression drives neuroinflammation and mechanical allodynia via a Ca2+-dependent CGRP/SP-Piezo2 signaling loop. These mechanistic insights clarify sensory neuron sensitization in trigeminal neuralgia, with implications for targeted modulation of pain pathways.

• SGC-CBP30 and the New Frontier in Super-Enhancer Targeting

  2026-04-23

  Translational researchers face mounting pressure to address the epigenetic drivers of early-stage lung adenocarcinoma (LUAD) progression. Recent insights into super-enhancer hijacking and TGF-β/SMAD3–mediated oncogenic signaling spotlight the CREBBP/EP300 axis as a mechanistically rich and clinically actionable node. This article bridges mechanistic discoveries—anchored by the landmark study of LINC01977 super-enhancer hijacking in LUAD—with strategic guidance for leveraging SGC-CBP30, a selective CREBBP/EP300 bromodomain inhibitor from APExBIO, as a transformative research tool. We detail protocol parameters, competitive context, and translational outlook, providing a nuanced narrative well beyond typical product summaries.

• Cytarabine (AraC): Precision Workflows in Leukemia Research

  2026-04-22

  Cytarabine (AraC) empowers researchers to dissect apoptosis and DNA synthesis inhibition with reproducible, mechanistically validated workflows. This guide details applied use-cases, protocol enhancements, and troubleshooting tips—backed by comparative insights from the latest viral cell death research and hands-on leukemia models.

• Assessing Ribociclib–Acid Reducer Interactions: A QbD Approa

  2026-04-22

  This study rigorously evaluates whether acid-reducing agents, such as proton pump inhibitors, significantly alter the solubility and absorption of ribociclib succinate, a key CDK4/6 inhibitor in HER2-positive breast cancer therapy. Using a Quality by Design (QbD)-driven analytical method, the authors demonstrate that pH shifts induced by these agents do not meaningfully impact ribociclib’s absorption, refining clinical guidance for oncological co-therapy.

454 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page